CY1112878T1 - Νεο αλας βενζοϋλογονανιδινης - Google Patents

Νεο αλας βενζοϋλογονανιδινης

Info

Publication number
CY1112878T1
CY1112878T1 CY20121100605T CY121100605T CY1112878T1 CY 1112878 T1 CY1112878 T1 CY 1112878T1 CY 20121100605 T CY20121100605 T CY 20121100605T CY 121100605 T CY121100605 T CY 121100605T CY 1112878 T1 CY1112878 T1 CY 1112878T1
Authority
CY
Cyprus
Prior art keywords
benzoylogonanidine
new salt
salt
new
trifluoromethylbenzoylguanidine
Prior art date
Application number
CY20121100605T
Other languages
Greek (el)
English (en)
Inventor
Christian Eickmeier
Peter Sieger
Volkmar Körner
Rolf Herter
Werner Rall
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of CY1112878T1 publication Critical patent/CY1112878T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20121100605T 2001-02-15 2012-07-06 Νεο αλας βενζοϋλογονανιδινης CY1112878T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz
EP02719831A EP1362030B1 (de) 2001-02-15 2002-02-14 Neues benzoylguanidinsalz

Publications (1)

Publication Number Publication Date
CY1112878T1 true CY1112878T1 (el) 2016-04-13

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100605T CY1112878T1 (el) 2001-02-15 2012-07-06 Νεο αλας βενζοϋλογονανιδινης

Country Status (31)

Country Link
US (2) US20080025919A1 (cg-RX-API-DMAC7.html)
EP (1) EP1362030B1 (cg-RX-API-DMAC7.html)
JP (3) JP4408626B2 (cg-RX-API-DMAC7.html)
KR (1) KR100862176B1 (cg-RX-API-DMAC7.html)
CN (1) CN1222510C (cg-RX-API-DMAC7.html)
AT (1) ATE553078T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002250939B2 (cg-RX-API-DMAC7.html)
BG (1) BG66330B1 (cg-RX-API-DMAC7.html)
BR (1) BR0207867A (cg-RX-API-DMAC7.html)
CA (1) CA2434829C (cg-RX-API-DMAC7.html)
CY (1) CY1112878T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303277B6 (cg-RX-API-DMAC7.html)
DE (1) DE10106970A1 (cg-RX-API-DMAC7.html)
DK (1) DK1362030T3 (cg-RX-API-DMAC7.html)
EA (1) EA006245B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034708A (cg-RX-API-DMAC7.html)
EE (1) EE200300393A (cg-RX-API-DMAC7.html)
ES (1) ES2385472T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030653B1 (cg-RX-API-DMAC7.html)
HU (1) HU230035B1 (cg-RX-API-DMAC7.html)
IL (1) IL156934A (cg-RX-API-DMAC7.html)
NO (1) NO20033299D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ528081A (cg-RX-API-DMAC7.html)
PL (1) PL213300B1 (cg-RX-API-DMAC7.html)
PT (1) PT1362030E (cg-RX-API-DMAC7.html)
RS (1) RS52014B (cg-RX-API-DMAC7.html)
SI (1) SI1362030T1 (cg-RX-API-DMAC7.html)
SK (1) SK287830B6 (cg-RX-API-DMAC7.html)
UA (1) UA74625C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002064563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305365B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof

Also Published As

Publication number Publication date
NO20033299L (no) 2003-07-22
HK1064093A1 (zh) 2005-01-21
RS52014B (sr) 2012-04-30
EP1362030A1 (de) 2003-11-19
JP2009235097A (ja) 2009-10-15
CN1491213A (zh) 2004-04-21
CA2434829C (en) 2009-12-08
BR0207867A (pt) 2004-03-23
IL156934A0 (en) 2004-02-08
BG108065A (bg) 2005-01-31
EE200300393A (et) 2003-12-15
JP2013107906A (ja) 2013-06-06
SK10202003A3 (sk) 2004-02-03
DK1362030T3 (da) 2012-07-09
UA74625C2 (en) 2006-01-16
CA2434829A1 (en) 2002-08-22
PL213300B1 (pl) 2013-02-28
EP1362030B1 (de) 2012-04-11
IL156934A (en) 2005-12-18
AU2002250939B2 (en) 2007-09-06
JP5745215B2 (ja) 2015-07-08
ZA200305365B (en) 2004-04-22
PT1362030E (pt) 2012-07-04
PL362129A1 (en) 2004-10-18
NO20033299D0 (no) 2003-07-22
CZ303277B6 (cs) 2012-07-11
EA006245B1 (ru) 2005-10-27
CZ20032210A3 (cs) 2003-12-17
SI1362030T1 (sl) 2012-07-31
BG66330B1 (bg) 2013-06-28
SK287830B6 (sk) 2011-11-04
HRP20030653A2 (en) 2005-06-30
HRP20030653B1 (en) 2012-06-30
JP2004518721A (ja) 2004-06-24
ATE553078T1 (de) 2012-04-15
HUP0303027A2 (hu) 2003-12-29
EA200300771A1 (ru) 2004-02-26
US20080025919A1 (en) 2008-01-31
ECSP034708A (es) 2003-12-24
KR20030075197A (ko) 2003-09-22
NZ528081A (en) 2005-10-28
JP4408626B2 (ja) 2010-02-03
CN1222510C (zh) 2005-10-12
US20080241077A1 (en) 2008-10-02
HU230035B1 (hu) 2015-05-28
YU61503A (sh) 2006-05-25
HUP0303027A3 (en) 2010-04-28
WO2002064563A1 (de) 2002-08-22
KR100862176B1 (ko) 2008-10-09
DE10106970A1 (de) 2002-08-29
ES2385472T3 (es) 2012-07-25

Similar Documents

Publication Publication Date Title
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
CY1114866T1 (el) Μεθοδος για την παραγωγη αμινοκροτονυλικων ενωσεων
CY1112916T1 (el) 3-ζ-1-(4-(ν-((4-μεθυλ-πιπεραζιν-1-υλ)-μεθυλκαρβονυλ)-ν-μεθυλ-αμινο)-ανιλινο)-1-φαινυλ-μεθυλενο-6-μεθοξυκαρβονυλ-2-ινδολινονη-μονοαιθανοσουλφονικη και η χρηση αυτης ως φαρμακευτικη συνθεση
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1114637T1 (el) 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο
ATE457025T1 (de) Kinaseinhibitoren
BRPI0820474B8 (pt) uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
CY1109956T1 (el) Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
CY1113566T1 (el) Καρβαμοϋλο-κυκλοεξανια για τη θεραπευτικη αγωγη της οξειας μανιας
ITRM20010126A0 (it) Metodo di abilitazione dell'interazione vocale di una pagina o di un sito web.
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
NO20040404L (no) 2- (3,5-bis-trifluorometyl-fenyl) - N - [6-(1,1-diokso-1lam bda6-tiomorfolin-4-yl) - 4 - (2-metyl- eller 4-fluor-2-metylsubstituert) fenyl-pyridin-3-yl] -N-metyl-isobutyrami.
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
SE0203302D0 (sv) Novel Compounds
IS8383A (is) Nýjar afleiður af 4a,5,9,10,11,12-hexahýdróbensófúró[3a,3,2][2]-bensasepín, aðferð við framleiðslu þeirra og notkun þeirra við framleiðslu á lyfjum
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
NO20043114L (no) Bredspektrede heterocyklisk substituerte fenylinneholdende sulfonamid-HIV-proteaseinhibitorer
EA200300771A1 (ru) Новая соль бензоилгуанидина
NO20043585L (no) Behandling av reumatoid artritt
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.